Protalix BioTherapeutics(PLX) - 2022 Q1 - Quarterly Report

OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 001-33357 FORM 10-Q (Commission file number) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 Delaware 65-0643773 (State or other jurisdiction of incorporation or organization) Securities registered pursuant to ...